# Factors Associated With Inaccurate Recall of Inherited Cancer Genetic Test Results Among Individuals With Germline Pathogenic Variants

## TL;DR

The study finds that 11% of people with cancer-related genetic mutations don't accurately recall their test results, which could affect their medical care.

## Contribution

The study identifies demographic and psychosocial factors linked to inaccurate recall of inherited cancer genetic test results.

## Key findings

- 11% of participants failed to accurately recall their genetic test results.
- Participants with cancer history and without a college degree were more likely to have inaccurate recall.
- Those with high-risk breast cancer genes were less likely to have inaccurate recall compared to other cancer gene carriers.

## Abstract

Germline pathogenic and likely pathogenic variants (GPV) in cancer susceptibility genes may guide medical care. However, inaccurate recall of test results by patients may impact the uptake of appropriate medical care, underscoring the importance of accurate recall of results.

Among individuals with a confirmed cancer susceptibility GPV that alters cancer risk management, individuals were categorized based on their accuracy of recall. Multiple logistic regression was performed to determine demographic and psychosocial factors associated with recall of test results.

Of 807 participants, 91 (11%) failed to accurately recall their test results, including 22 who did not remember being tested and 69 whose cancer risk management could be impacted due to inaccurate recall of test result details. Compared to those with accurate recall of test results, those who failed to accurately recall their results were significantly more likely to have a history of cancer [OR = 2.24, p = 0.009] and lack a college degree [OR = 2.42, p < 0.029]. Additionally, based on standardized survey responses, failure to accurately recall was associated with positive feelings about their results [OR = 1.73, p < 0.001], lower emotional distress [OR = 0.65, p = 0.004], lower knowledge about hereditary cancer [OR = 0.67, p < 0.001], and lower satisfaction with family communication and support related to testing [OR = 0.62, p < 0.001]. Participants with GPVs in high‐risk or moderate‐risk breast cancer genes were substantially less likely to demonstrate inaccurate recall (both OR = 0.18, p < 0.001) compared to those with GPVs in other actionable cancer genes.

Given 11% of participants failed to remember being tested or failed to accurately recall their result, this highlights the importance of documentation and accessibility of test results by both patients and providers to ensure patients receive appropriate care.